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A B S T R A C T   
The Elecsys® Anti-SARS-CoV-2 S immunoassay (Roche Diagnostics International Ltd, Rotkreuz, Switzerland) has 
been developed for the detection of antibodies to the severe acute respiratory syndrome coronavirus 2 (SARS- 
CoV-2) spike (S) protein. We evaluated the assay performance using samples from seven sites in Germany, 
Austria, and Switzerland. For specificity and sensitivity analyses, 7880 presumed negative pre-pandemic samples 
and 827 SARS-CoV-2 PCR-confirmed single or sequential samples from 272 different patients were tested, 
respectively. The overall specificity and sensitivity (≥14 days post-PCR) for the Elecsys Anti-SARS-CoV-2 S 
immunoassay were 99.95% (95% confidence interval [CI]: 99.87–99.99; 7876/7880) and 97.92% (95% CI: 
95.21–99.32; 235/240), respectively. The Elecsys Anti-SARS-CoV-2 S immunoassay had significantly higher 
specificity compared with the LIAISON® SARS-CoV-2 S1/S2 IgG (99.95% [2032/2033] vs 98.82% [2009/ 
2033]), ADVIA Centaur® SARS-CoV-2 Total (100% [928/928] vs 86.96% [807/928]), ARCHITECT SARS-CoV-2 
IgG (99.97% [2931/2932] vs 99.69% [2923/2932]), iFlash-SARS-CoV-2 IgM (100.00% [928/928] vs 99.57% 
[924/928]), and EUROIMMUN Anti-SARS-CoV-2 IgG (100.00% [903/903] vs 97.45% [880/903]) and IgA 
(100.00% [895/895] vs 95.75% [857/895]) assays. The Elecsys Anti-SARS-CoV-2 S immunoassay had signifi-
cantly higher sensitivity (≥14 days post-PCR) compared with the ARCHITECT SARS-CoV-2 IgG (98.70% [76/77] 
vs 87.01% [67/77]), iFlash-SARS-CoV-2 IgG (100.00% [76/76] vs 93.42% [71/76]) and IgM (100.00% [76/76] 
vs 35.53% [27/76]), and EUROIMMUN Anti-SARS-CoV-2 IgG (98.26% [113/115] vs 93.91% [108/115]) assays. 
Therefore, the Elecsys Anti-SARS-CoV-2 S assay demonstrated a reliable performance across various sample 
populations for the detection of anti-S antibodies.   
1. Introduction 
In December 2019 a novel coronavirus emerged (Chan et al., 2020), 
named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 
which is the causative agent of the disease, COVID-19 (Wu et al., 2020; 
World Health Organization, 2020). SARS-CoV-2 is an enveloped, 
single-stranded RNA virus of the family Coronaviridae; its genome en-
codes 16 nonstructural proteins and four structural proteins: spike (S), 
envelope (E), membrane (M), and nucleocapsid (N) (Naqvi et al., 2020). 
The most prominent protein component on the viral surface is the S 
glycoprotein – a large transmembrane protein that assembles into trimers 
to form the distinctive surface spikes of coronaviruses (Walls et al., 2020; 
Tang et al., 2020). Each S monomer consists of two subunits, S1 and S2, 
which mediate receptor binding (via the receptor-binding domain [RBD] 
located in S1) and membrane fusion, respectively, leading to entry into 
host cells (Tang et al., 2020; Wrapp et al., 2020; Ou et al., 2020). 
Following SARS-CoV-2 infection, the host mounts an immune 
response against the virus, including production of specific antibodies 
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against viral antigens (Galipeau et al., 2020). Understanding the dy-
namics of the antibody response to the virus is critical in establishing a 
relevant time window to use for serology testing (Galipeau et al., 2020). 
Studies into the kinetics of antibodies to SARS-CoV-2 are rapidly 
emerging and, both immunoglobulin M (IgM) and G (IgG) antibodies 
have been detected as early as day 1 after symptom onset (Guo et al., 
2020). The chronological order of appearance and levels of IgM and IgG 
seems to be highly variable and often simultaneous (To et al., 2020; Long 
et al., 2020; Zhao et al., 2020). Several studies have observed median 
seroconversion at day 10–13 after symptom onset for IgM and day 12–15 
for IgG, with maximum seroconversion for IgM, IgG, and total antibodies 
occurring at week 2–3, week 2–4, and around week 2, respectively (Long 
et al., 2020; Zhao et al., 2020; Lou et al., 2020; Young et al., 2020). 
Emergence of the COVID-19 pandemic has resulted in an urgent and 
unmet need to develop reliable serological tests to determine past expo-
sure to the virus and the seroprevalence in a given population (Kontou 
et al., 2020). This information is crucial to support diagnosis, contact 
tracing, epidemiological studies, and vaccine development to enable 
characterization of pre-vaccination immune status and vaccine-induced 
immune response (Galipeau et al., 2020; Ernst et al., 2021; Zhu et al., 
2020; Widge et al., 2021). There are currently 294 candidate SARS-CoV-2 
vaccines in development (status August 03, 2021) (World Health Orga-
nization, 2021) and, of these, 17 are currently in early, limited, or fully 
approved use (status July 07, 2021) (Gavi, 2021). The majority of the 
vaccines in use are based on the S protein, with the goal of eliciting 
protective neutralizing antibodies; the rest are based on whole inactivated 
SARS-CoV-2 (Dai and Gao, 2021; Forni and Mantovani, 2021). Serology 
assays are also needed for the identification of neutralizing antibodies 
from convalescent plasma donors (Ni et al., 2020). 
The Elecsys® Anti-SARS-CoV-2 S (Roche Diagnostics International 
Ltd, Rotkreuz, Switzerland) is an electrochemiluminescence immuno-
assay (ECLIA), which has been developed for the in vitro quantitative 
detection of antibodies, including IgG, against the SARS-CoV-2 S protein 
RBD in human serum and plasma (Roche Diagnostics GmbH, 2021a). 
The objective of this multicenter European study was to qualitatively 
evaluate the specificity and sensitivity of the Elecsys Anti-SARS-CoV-2 S 
immunoassay using pre-pandemic samples (from routine diagnostics or 
blood donation) and polymerase chain reaction (PCR)-positive samples, 
respectively, as well as compare the performance of this quantitative test 
with other commercially available immunoassays in terms of specificity 
and sensitivity. 
2. Materials and methods 
2.1. Study design 
The study was executed from August 17, 2020 to September 1, 2020 
with samples tested at four European sites: Labor Augsburg MVZ GmbH, 
Augsburg, Germany; MVZ Labor Dr. Limbach & Kollegen GbR, Heidel-
berg, Germany; Interregionale Blutspende SRK AG (SRK Bern), Bern, 
Switzerland; and Krankenhaus Barmherzige Brüder, Regensburg, Ger-
many. Samples were collected from those four sites, as well as from three 
additional sites: Labor Berlin – Charité Vivantes GmbH, Berlin, Ger-
many; Tirol Kliniken, Innsbruck, Austria; and Deutsches Rotes Kreuz 
Blutspendedienst West, Hagen, Germany. 
Samples from Augsburg and Heidelberg included those referred to 
the respective study site by physicians. Heidelberg also tested samples 
from employees and hospitalized patients, including a subset from pa-
tients receiving dialysis. All samples provided by the study site in Berlin 
were collected from hospitalized patients, including a subset from pa-
tients monitored in the intensive care unit. Samples tested in Regensburg 
were taken from employees and pediatric patients referred to the site by 
physicians. 
These samples were collected and tested in accordance with appli-
cable regulations, including relevant European Union directives and 
regulations, and the principles of the Declaration of Helsinki. All samples 
from Augsburg, Heidelberg, Berlin and Hagen were anonymized. A 
statement was obtained from the Ethics Committee (EC) of the Land-
esärztekammer Bayern confirming that there are no objections to the use 
of anonymized leftover samples. From the EC at the study site in Bern 
(Switzerland) a waiver was received and from the internal EC at the study 
site in Innsbruck (Austria) an approval was received. For Regensburg 
(Germany), EC approvals were already in place, amendments were sub-
mitted to notify the EC about Elecsys Anti-SARS-CoV-2 S testing. At 
Augsburg, Heidelberg, and Bern the assays were performed on the cobas 
e 801 analyzer (Roche Diagnostics International Ltd, Rotkreuz, 
Switzerland), whereas at Regensburg the assays were performed on the 
cobas e 601 analyzer (Roche Diagnostics International Ltd, Rotkreuz, 
Switzerland). To assess the proper function of cobas e instruments, ap-
plications and reagents, a familiarization experiment was performed with 
quality control material and successfully passed at all measuring sites. 
Sites were requested to run quality controls after every calibration, for 
each reagent kit, and at least once every 24 h, and to proceed only if the 
recovery was within the acceptance criteria. 
2.2. Serum and plasma samples 
Anonymized frozen, residual serum or plasma samples (≥300 μl 
volume) from blood donation centers or routine laboratory di-
agnostics, as well as banked samples, were used for this study. For 
specificity analysis of the Elecsys Anti-SARS-CoV-2 S assay, 7880 
samples (5056 blood donor and 2824 diagnostic routine samples) that 
were collected before the COVID-19 pandemic in October 2019, and 
therefore presumed to be negative for SARS-CoV-2, were tested. The 
diagnostic routine cohort included samples from women attending 
pregnancy screening and from pediatrics. For the sensitivity analysis 
of the Elecsys Anti-SARS-CoV-2 S assay, 827 PCR-confirmed single or 
sequential samples from 272 different patients, with known time dif-
ference between blood draw and positive PCR test, were tested. Of 
these presumed negative and PCR-confirmed samples, 7903 were 
tested on the commercially available Elecsys® Anti-SARS-CoV-2 assay 
(Roche Diagnostics International Ltd, Rotkreuz, Switzerland) (Roche 
Diagnostics GmbH, 2021b). Additionally, a number of these samples 
were tested on other commercially available assays: LIAISON® 
SARS-CoV-2 S1/S2 IgG (DiaSorin, Saluggia, Italy) (DiaSorin, 2020), 
2052 samples; EUROIMMUN Anti-SARS-CoV-2 IgG (EUROIMMUN, 
2020a) and immunoglobulin A (IgA) assays (EUROIMMUN, Lübeck, 
Germany) (EUROIMMUN, 2020b), 1618 and 1624 samples, respec-
tively; ARCHITECT SARS-CoV-2 IgG (Abbott Laboratories, Abbott 
Park, Illinois, USA) (Abbott, 2021), 3068 samples; ADVIA Centaur® 
SARS-CoV-2 Total (Siemens, Tarrytown, New York, USA) (Siemens, 
2020), 1064 samples; iFlash-SARS-CoV-2 IgG and IgM assays (YHLO 
Biotech Co., Ltd, Shenzhen, China) (Shenzhen YHLO Biotech Co Ltd., 
2020), both 1062 samples. 
2.3. Elecsys Anti-SARS-CoV-2 S assay 
The Elecsys Anti-SARS-CoV-2 S immunoassay is a quantitative ECLIA 
that detects high-affinity antibodies to the SARS-CoV-2 S protein RBD 
and has a low risk of detecting weakly cross-reactive and unspecific 
antibodies. Results are automatically reported as the analyte concen-
tration of each sample in U/mL, with <0.80 U/mL interpreted as 
negative for anti-SARS-CoV-2 S antibodies and ≥0.80 U/mL interpreted 
as positive for anti-SARS-CoV-2 S antibodies (Roche Diagnostics GmbH. 
Elecsys Anti-SARS-CoV-2 S assay method sheet. 2020; version 2.0) 
(Roche Diagnostics GmbH, 2021c). 
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2.4. Comparator assays 
Specimens were analyzed using eight comparator immunoassays 
according to the manufacturer’s instructions. Interpretation of results 
was performed according to the manufacturer’s instructions. 
The Elecsys Anti-SARS-CoV-2 assay is an ECLIA for the in vitro qual-
itative detection of antibodies, including IgG, against SARS-CoV-2, using 
a recombinant protein representing the N antigen (Roche Diagnostics 
GmbH, 2021b). Results are automatically calculated in the form of a 
cutoff index (COI), with values <1.0 interpreted as non-reactive (nega-
tive) for anti-SARS-CoV-2 N antibodies and ≥1.0 as reactive (positive) for 
anti-SARS-CoV-2 N antibodies (Roche Diagnostics GmbH, 2021b). 
The LIAISON SARS-CoV-2 S1/S2 IgG assay is an indirect chem-
iluminescence immunoassay (CLIA) for the quantitative detection of IgG 
anti-S1 and IgG anti-S2 antibodies to SARS-CoV-2 (DiaSorin, 2020). 
Results are automatically calculated, with antibody concentrations 
expressed as arbitrary units (AU/mL). Concentrations of <12.0 AU/mL 
are interpreted as negative, ≥12.0 to <15.0 AU/mL are interpreted as 
equivocal, and ≥15.0 AU/mL are interpreted as positive (DiaSorin, 
2020). Equivocal values are referred to as ‘gray zone’ results. 
The EUROIMMUN Anti-SARS-CoV-2 IgG and IgA assays are separate 
enzyme-linked immunosorbent assays (ELISAs) that detect IgG or IgA 
anti-S1 antibodies to SARS-CoV-2 (EUROIMMUN, 2020a, b). Results are 
evaluated semi-quantitatively by calculation of a ratio in which the 
absorbance values of the controls or patient samples are related to the 
absorbance value of the calibrator (EUROIMMUN, 2020a, b). For both 
assays, ratio results <0.8 are interpreted as negative, ≥0.8 to <1.1 are 
borderline, and ≥1.1 are positive (EUROIMMUN, 2020a, b). Borderline 
values are referred to as ‘gray zone’ results. 
The ARCHITECT SARS-CoV-2 IgG assay is a chemiluminescent 
microparticle immunoassay (CMIA) used for the qualitative detection of 
IgG antibodies against the N antigen (Abbott, 2021). Results are 
expressed in signal-to-cutoff (S/CO) values, with <1.4 results interpreted 
as negative and ≥1.4 results interpreted as positive (Abbott, 2021). 
The ADVIA Centaur SARS-CoV-2 Total assay is a CLIA intended for 
the qualitative detection of antibodies against the RBD of the S1 protein 
(Siemens, 2020). Results are reported in index values, with <1.0 inter-
preted as non-reactive (negative) for anti-SARS-CoV-2 antibodies and 
≥1.0 interpreted as reactive (positive) for anti-SARS-CoV-2 antibodies 
(Siemens, 2020). 
The iFlash-SARS-CoV-2 IgM and IgG assays (Shenzhen YHLO Biotech 
Co Ltd., 2020) are separate CLIAs used for the qualitative detection of 
IgM or IgG against the S and N proteins. The iFlash system automatically 
calculates the analytic concentration of each sample, with <10 AU/mL 
interpreted as non-reactive and ≥10 AU/mL interpreted as reactive for 
anti-SARS-CoV-2 IgM or IgG antibodies. 
2.5. Statistical analysis 
Sample size estimations for specificity and sensitivity analyses were 
based on formulae proposed previously (Hajian-Tilaki, 2014). Assuming 
specificities between 0.998 and 0.999 and a sensitivity of 0.999, samples 
sizes of 1698–20964 and 32–50 respectively, would be required to 
obtain a significance level of 0.05 and a power of 0.8. For specificity and 
sensitivity calculations, point estimates and two-sided 95% confidence 
intervals (CIs) using the exact method were computed employing R 
version 3.4.0 (R Core Team, 2017). In the sensitivity evaluation, assay 
results were assigned to the respective week after positive PCR result. In 
the comparison with other commercially available assays, only samples 
with paired measurements were included in the respective analyses. For 
the differences in estimated specificities and sensitivities between 
Elecsys Anti-SARS-CoV-2 S assay and the comparator assays, two-sided 
95% Wald CIs were calculated as previously recommended (Wenzel and 
Zapf, 2013). If these CIs did not include zero, differences were consid-
ered as statistically significant. 
3. Results 
3.1. Overall performance of the elecsys Anti-SARS-CoV-2 S assay 
3.1.1. Specificity in different target cohorts 
Specificity of the Elecsys Anti-SARS-CoV-2 S assay was evaluated at 
three European sites (with samples from five European sites) using 7880 
evaluable residual samples from blood donors and routine diagnostic 
testing; all of which were collected before October 2019 and presumed 
negative for SARS-CoV-2 antibodies. The overall specificity for all 
samples was 99.95% (95% CI: 99.87–99.99 [7876/7880]) (Table 1). 
There were four samples with reactive results of 1.790 U/mL, 0.900 U/ 
mL, 0.870 U/mL, and 1.130 U/mL. Three of these reactive samples were 
from blood donor samples, of which one was collected in March 2016 
(influenza season) at Innsbruck, Austria and two were collected in July/ 
August 2018 (outside influenza season) at Bern, Switzerland (Table 1). 
There was no statistically significant difference in specificity between 
blood donor samples collected during or outside influenza season. The 
other reactive sample was from the pregnancy screening cohort in 
Augsburg (Table 1). 
3.1.2. Sensitivity in different target cohorts 
In total, 827 single and sequential samples from 272 SARS-CoV-2 
PCR-confirmed patients were evaluated at three European sites (with 
samples from four European sites). The time span of samples collected 
after positive PCR was between day 0 and day 120. For subjects with 
sequential blood draws with more than one sample per time interval, 
only the result of the last blood draw per given time interval was used for 
the respective sensitivity calculation. The sensitivity of the Elecsys Anti- 
SARS-CoV-2 S assay ≥14 days post-PCR (n = 240) was 97.92% (95% CI: 
95.21–99.32 [235/240]) (Table 2). The resulting site-specific sensitiv-
ities for Augsburg, Berlin, Heidelberg, and Regensburg samples collected 
≥14 days post-PCR confirmation were 100.00% (95% CI: 95.89–100.00), 
100.00% (95% CI: 91.40–100.00), 98.72% (95% CI: 93.06–99.97%), and 
87.88% (95% CI: 71.80–96.60), respectively. 
3.1.3. Determination of seroconversions 
For all subjects with at least two sequential blood draws, trajectories 
were plotted to determine antibody titer development from day 0–78 
post-PCR-positive test (Fig. 1). Most trajectories showed a rapid increase 
Table 1 
Specificity results for the Elecsys Anti-SARS-CoV-2 S assay.  




confidence intervals, 2- 
sided) 




influenza season 1/1050 99.90% (99.47–100.00) 
Hagen / no 
seasonal selection 
0/955 100.00% (99.61–100.00) 
Bern / outside 
influenza season 
2/2000 99.90% (99.64–99.99) 
Bern / influenza 
season 0/1051 100.00% (99.65–100.00) 
Total blood donors 3/5056 99.94% (99.83–99.99) 













0/737 100.00% (99.50–100.00) 
Heidelberg / 
pediatric samples 
0/191 100.00% (98.09–100.00) 
Total diagnostic routine 1/2824 99.96% (99.80–100.00) 
Overall (all samples) 4/7880 99.95% (99.87–99.99)  
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in antibody titer and no considerable decline of antibody titer was seen 
for the early and later blood draws. Once detected reactive, none of the 
subsequent samples drawn per subject showed a decline of titer below 
the cutoff. 
3.2. Comparison with Elecsys Anti-SARS-CoV-2 assay 
A direct method comparison between the Elecsys Anti-SARS-CoV-2 S 
assay and the commercially available Elecsys Anti-SARS-CoV-2 assay 
was performed. This included a total of 7903 samples comprising both 
confirmed positive samples from sensitivity testing and presumed pos-
itive samples with at least one positive antibody result (n = 1011), as 
well as presumed negative samples from specificity testing cohort 
samples (n = 6892: n = 4068 blood donors; n = 2824 routine diag-
nostic). For all samples, the overall percent agreement (OPA) between 
the Elecsys Anti-SARS-CoV-2 S assay and the Elecsys Anti-SARS-CoV-2 
assay was 99.30% (95% CI: 99.10–99.48) (Supplemental Table 1). 
3.3. Comparison with other commercially available assays 
The performance of the Elecsys Anti-SARS-CoV-2 S immunoassay was 
compared with seven other commercially available SARS-CoV-2 assays, 
and sensitivity and specificity results, along with percent agreement, 
were recorded. Information regarding the different assays, including the 
technique, target, and Ig measured can be found in Supplemental Table 2. 
The OPA between the Elecsys Anti-SARS-CoV-2 S assay and other 
comparator tests was recorded (Supplemental Table 2). The Elecsys 
Anti-SARS-CoV-2 S test had the highest OPA with the ARCHITECT SARS- 
CoV-2 IgG (N-assay), at 99.19% (95% CI: 98.80–99.47), and the lowest 
OPA with the ADVIA Centaur SARS-CoV-2 Total (S-assay), at 88.25% 
(95% CI: 86.16–90.13) (Supplemental Table 3). 
3.3.1. Specificity 
The specificity of the Elecsys Anti-SARS-CoV-2 S assay was compa-
rable or higher than the specificity of all tested comparator assays 
(Table 3). The specificity of the Elecsys Anti-SARS-CoV-2 S test was 
significantly higher compared with the LIAISON SARS-CoV-2 S1/S2 IgG 
(99.95% [2032/2033] vs 98.82% [2009/2033]), ADVIA Centaur SARS- 
CoV-2 Total (100% [928/928] vs 86.96% [807/928]), ARCHITECT 
SARS-CoV-2 IgG (99.97% [2931/2932] vs 99.69% [2923/2932]), 
iFlash-SARS-CoV-2 IgM (100.00% [928/928] vs 99.57% [924/928]), 
and EUROIMMUN Anti-SARS-CoV-2 IgG (100.00% [903/903] vs 
97.45% [880/903]) and IgA (100.00% [895/895] vs 95.75% [857/ 
895]) assays (Table 3, Supplemental Table 4A). No statistically signifi-
cant difference was observed between the specificity of the Elecsys Anti- 
SARS-CoV-2 S assay compared with the iFlash-SARS-CoV-2 IgG assay, 
which was 100.00% (928/928) for both assays (Table 3, Supplemental 
Table 4A). 
3.3.2. Sensitivity 
The sensitivity of the Elecsys Anti-SARS-CoV-2 S assay for detecting 
seropositive results was compared with six comparator assays; analysis 
compared with the LIAISON SARS-CoV-2 S1/S2 IgG test could not be 
performed due to a small sample size. Sensitivity was recorded for 
samples collected between 0–6, 7–13, and ≥14 days post-PCR-positive 
test (Table 4). The EUROIMMUN Anti-SARS-CoV-2 IgA assay showed 
a higher sensitivity in the 0–6 (59.09% [26/44] vs 56.82% [25/44]) and 
7–13 days (91.84% [45/49] vs 85.71% [42/49]) post-PCR time intervals 
and a lower sensitivity in the ≥14 days (97.46% [115/118] vs 99.15% 
[117/118]) post-PCR time interval compared with the Elecsys Anti- 
SARS-CoV-2 S assay (Table 4). The sensitivity of the Elecsys Anti- 
SARS-CoV-2 S assay at detecting antibodies ≥14 days post-PCR was 
significantly higher compared with the ARCHITECT SARS-CoV-2 IgG 
(98.70% [76/77] vs 87.01% [67/77]), iFlash-SARS-CoV-2 IgG 
(100.00% [76/76] vs 93.42% [71/76]) and IgM (100.00% [76/76] vs 
35.53% [27/76]), and EUROIMMUN Anti-SARS-CoV-2 IgG (98.26% 
[113/115] vs 93.91% [108/115]) assays (Table 4, Supplemental 
Table 4B). 
Table 2 




number of samples 
Sensitivity (95% confidence 
intervals, 2-sided) 
0 to 6 19/44 56.82% (41.03–71.65) 
7 to 13 7/49 85.71% (72.76–94.06) 
14 to 20 1/47 97.87% (88.71–99.95) 
21 to 27 0/58 100.00% (93.84–100.00) 
28 to 34 0/43 100.00% (91.78–100.00) 
35 to 41 1/57 98.25% (90.61–99.96) 
42 to 48 0/47 100.00% (92.45–100.00) 
49 to 55 4/39 89.74% (75.78–97.13) 
56 to 62 0/33 100.00% (89.42–100.00) 
≥63 (up to 120) 0/21 100.00% (83.89–100.00) 
All samples ≥14 
(up to 120)a 
5/240 97.92% (95.21–99.32) 
PCR, polymerase chain reaction. 
a Only the last sample taken ≥14 days post-PCR of each patient is included in 
the sensitivity calculation. 
Fig. 1. Longitudinal antibody titers of all subjects. Concentration 
of anti-S SARS-CoV-2 antibodies, as measured by the Elecsys Anti-S 
SARS-CoV-2 S immunoassay, over time (days 0 to 78) in sequential 
samples from all study sites. Each grey circle represents a different 
data point, with darker circles representing overlapping data 
points. The solid blue line represents the combined curve, and the 
blue dashed lines represent the upper and lower confidence limits. 
The red dashed line indicates the assay cutoff limit (0.80 U/mL).   
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4. Discussion 
Due to the COVID-19 pandemic, there is a pressing need to develop 
highly specific and sensitive serology tests to assist with the diagnosis of, 
and to reveal past exposure to, the SARS-CoV-2 virus (Kontou et al., 
2020), as well as to support the development of vaccines through dis-
tinguishing natural infection-induced immunity from vaccine-induced 
immunity (Galipeau et al., 2020; Ernst et al., 2021). This was the first 
multicenter study to demonstrate the performance of the automated 
Elecsys Anti-SARS-CoV-2 S immunoassay, which detects antibodies 
against the SARS-CoV-2 S protein RBD. Antibodies against the RBD have 
previously been shown to correlate strongly with protective neutralizing 
antibodies (Premkumar et al., 2020). 
The results from our study revealed that the Elecsys Anti-SARS-CoV- 
2 S immunoassay displays a robust performance under routine condi-
tions at multiple sites in Europe, with a very high specificity (99.95% 
[7876/7880]) and sensitivity (97.92% [235/240]) for the detection of 
anti-S antibodies. The point estimates for specificity and sensitivity are 
comparable to the values reported in the package insert of the Elecsys 
Anti-SARS-CoV-2 S assay (99.98% and 98.8%, respectively) (Roche 
Diagnostics GmbH, 2021a). In addition, the Elecsys Anti-SARS-CoV-2 S 
assay showed a performance comparable with the commercially 
available Elecsys Anti-SARS-CoV-2 (N-assay), with 95% CIs that over-
lap (99.69–99.88% for specificity and 97.0–100% for sensitivity); both 
assays had a very high overall percent agreement. The Elecsys 
Anti-SARS-CoV-2 assay has a previously reported specificity and 
sensitivity ≥14 days post-confirmation of 99.8% and 99.5%, respec-
tively (Muench et al., 2020). These data indicate that the Elecsys 
Anti-SARS-CoV-2 S assay can be utilized to meet the current need for 
anti-SARS-CoV-2 antibody testing, alongside or in place of the Elecsys 
Anti-SARS-CoV-2 (N) assay, depending on the study objectives. 
The overall specificity of >99.9% determined in this study demon-
strated that the Elecsys Anti-SARS-CoV-2 S is a highly specific assay for 
the detection of antibodies against SARS-CoV-2. Notably, this analysis 
included 2424 samples from pregnant women and pediatric populations. 
The availability of an accurate SARS-CoV-2 serology assay is particularly 
important for the pregnant population, considering the changes in the 
immune system that occur during pregnancy, which may increase the 
woman’s susceptibility to severe infection (Dashraath et al., 2020). 
Additionally, an antibody assay with a high specificity is imperative to 
reduce the risk of false-positive results, which may inaccurately indicate 
a past SARS-CoV-2 infection (Farnsworth and Anderson, 2020). Our 
study did not assess the specificity of the Elecsys Anti-SARS-CoV-2 S 
assay using samples from individuals with other respiratory infections. 
However, this assay has been previously tested using 1468 samples 
containing potentially cross-reactive samples collected before October 
2019, and 100% specificity was obtained with no cross-reactivity (Roche 
Diagnostics GmbH, 2021c). These samples were from individuals 
confirmed to be infected with MERS-CoV, common cold coronaviruses, 
or other respiratory infections (Roche Diagnostics GmbH, 2021c). 
The Elecsys Anti-SARS-CoV-2 S immunoassay demonstrated good 
specificity (99.95–100.00%) and sensitivity at ≥14 days post-PCR- 
positive test (98.26–100.00%) in direct comparison with other 
commercially available assays; both performance measurements were 
equal to or greater than those for other evaluated comparator assays. 
These other assays have also been assessed in previous studies (Kontou 
et al., 2020; Meyer et al., 2020; Kohmer et al., 2020; Okba et al., 2020; 
Ocmant et al., 2021). However, it is important to note that, for a direct 
comparison of sensitivity, the available assays differ with respect to 
assay designs (e.g. antibody classes used) as well as the targets (anti-N 
and anti-S) that they detect. 
A multicenter comparison of seven serology assays, including the 
Elecsys Anti-SARS-CoV-2 assay, revealed a subpopulation of PCR- 
confirmed SARS-CoV-2 individuals who were persistently seronega-
tive, which represents a proportion of patients who may be at risk for re- 
infection (Oved et al., 2020). Within the group of PCR-confirmed 
Table 3 
Specificity of the Elecsys Anti-SARS-CoV-2 S assay and other comparator assays.  
Assay Reactive samples/ number of samples Specificity (95% confidence intervals, 2-sided) 
Comparison with anti-S assays 
LIAISON SARS-CoV-2 S1/S2 IgG (GZ excl.)a 24/2033 98.82% (98.25–99.24) 
Elecsys Anti-SARS-CoV-2 S 1/2033 99.95% (99.73–100.00) 
LIAISON SARS-CoV-2 S1/S2 IgG (GZ+)a 31/2040 98.48% (97.85–98.97) 
Elecsys Anti-SARS-CoV-2 S 1/2040 99.95% (99.73–100.00) 
ADVIA Centaur SARS-CoV-2 Total 121/928 86.96% (84.62–89.06) 
Elecsys Anti-SARS-CoV-2 S 0/928 100.00% (99.60–100.00) 
EUROIMMUN Anti-SARS-CoV-2 IgG (GZ excl.) 23/903 97.45% (96.20–98.38) 
Elecsys Anti-SARS-CoV-2 S 0/903 100.00% (99.59–100.00) 
EUROIMMUN Anti-SARS-CoV-2 IgG (GZ+) 44/924 95.24% (93.66–96.52) 
Elecsys Anti-SARS-CoV-2 S 0/924 100.00% (99.60–100.00) 
EUROIMMUN Anti-SARS-CoV-2 IgA (GZ excl.) 38/895 95.75% (94.22–96.98) 
Elecsys Anti-SARS-CoV-2 S 0/895 100.00% (99.59–100.00) 
EUROIMMUN Anti-SARS-CoV-2 IgA (GZ+) 71/928 92.35% (90.45–93.98) 
Elecsys Anti-SARS-CoV-2 S 0/928 100.00% (99.60–100.00) 
Comparison with anti-N assay 
ARCHITECT SARS-CoV-2 IgG 9/2932 99.69% (99.42–99.86) 
Elecsys Anti-SARS-CoV-2 S 1/2932 99.97% (99.81–100.00) 
Comparison with anti-S and -N assays 
iFlash-SARS-CoV-2 IgG 0/928 100.00% (99.60–100.00) 
Elecsys Anti-SARS-CoV-2 S 0/928 100.00% (99.60–100.00) 
iFlash-SARS-CoV-2 IgM 4/928 99.57% (98.90–99.88) 
Elecsys Anti-SARS-CoV-2 S 0/928 100.00% (99.60–100.00) 
GZ, gray zone. 
a For antibody assays with a gray zone, two calculations were performed. In the first calculation, all gray zone results were excluded from the analysis (GZ excl.) and 
in the second calculation these results were interpreted as reactive (GZ+). 
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samples in our study, for which there was at least one S and one N 
antibody result from another comparator assay, there were samples 
from five patients all of which had a reactive Elecsys Anti-SARS-CoV-2 S 
ECLIA result, a reactive or ‘gray zone’ EUROIMMUN ELISA result and a 
reactive ADVIA Centaur CLIA result (S-assays), and a non-reactive 
Elecsys Anti-SARS-CoV-2 ECLIA and ARCHITECT SARS-CoV-2 IgG 
CMIA result (N-assays). There was only one sample that was commonly 
non-reactive in all S-based assays and reactive in all N-based assays. 
However, the blood draw was taken very early, on the same day as the 
PCR was done, and the follow-up sample was reactive with the Elecsys 
Anti-SARS-CoV-2 S assay. Data indicating differences in the kinetics of 
serology assays are ambiguous and there was little difference in the 
Table 4 
Sensitivity of the Elecsys Anti-SARS-CoV-2 S assay and other comparator assays.  
Assay Days post-PCR-positive test Non-reactive samples/ number of samples Sensitivity (95% confidence intervals, 2-sided) 
Comparison with anti-S assays 
ADVIA Centaur SARS-CoV-2 Total 0–6 8/18 55.56% (30.76–78.47)  
8/18 55.56% (30.76–78.47)  
7–13 
2/11 81.82% (48.22–97.72) 
Elecsys Anti-SARS-CoV-2 S 2/11 81.82% (48.22–97.72)  
≥14 
4/77 94.81% (87.23–98.57)  
1/77 98.70% (92.98–99.97) 
EUROIMMUN Anti-SARS-CoV-2 IgG 
(GZ excl.)a 0–6 21/43 51.16% (35.46–66.69)  
18/43 58.14% (42.13–72.99)  
7–13 7/45 84.44% (70.54–93.51) 
Elecsys Anti-SARS-CoV-2 S 7/45 84.44% (70.54–93.51)  
≥14 
7/115 93.91% (87.86–97.52)  
2/115 98.26% (93.86–99.79) 
EUROIMMUN Anti-SARS-CoV-2 IgG 
(GZ+)a 0–6 21/44 52.27% (36.69–67.54)  
19/44 56.82% (41.03–71.65)  
7–13 
7/49 85.71% (72.76–94.06) 
Elecsys Anti-SARS-CoV-2 S 7/49 85.71% (72.76–94.06)  
≥14 6/119 94.96% (89.35–98.13)  
1/119 99.16% (95.41–99.98) 
EUROIMMUN Anti-SARS-CoV-2 IgA 
(GZ excl.) 0–6 
18/44 59.09% (43.25–73.66)  
19/44 56.82% (41.03–71.65)  
7–13 
4/49 91.84% (80.40–97.73) 
Elecsys Anti-SARS-CoV-2 S 7/49 85.71% (72.76–94.06)  
≥14 
3/118 97.46% (92.75–99.47)  
1/118 99.15% (95.37–99.98) 
EUROIMMUN Anti-SARS-CoV-2 IgA 
(GZ+) 0–6 
18/44 59.09% (43.25–73.66)  
19/44 56.82% (41.03–71.65)  
7–13 4/49 91.84% (80.40–97.73) 
Elecsys Anti-SARS-CoV-2 S 7/49 85.71% (72.76–94.06)  
≥14 
3/121 97.52% (92.93–99.49)  
1/121 99.17% (95.48–99.98) 
Comparison with anti-N assay 
ARCHITECT SARS-CoV-2 IgG 
0–6 
9/18 50.00% (26.02–73.98)  
8/18 55.56% (30.76–78.47)  
7–13 
2/11 81.82% (48.22–97.72) 
Elecsys Anti-SARS-CoV-2 S 2/11 81.82% (48.22–97.72)  
≥14 10/77 87.01% (77.41–93.59)  
1/77 98.70% (92.98–99.97) 
Comparison with anti-S and -N assays 
iFlash-SARS-CoV-2 IgG 0–6 8/17 52.94% (27.81–77.02)  
7/17 58.82% (32.92–81.56)  
7–13 
2/11 81.82% (48.22–97.72) 
Elecsys Anti-SARS-CoV-2 S 2/11 81.82% (48.22–97.72)  
≥14 5/76 93.42% (85.31–97.83)  
0/76 100.00% (95.26–100.00) 
iFlash-SARS-CoV-2 IgM 
0–6 
11/17 35.29% (14.21–61.67)  
7/17 58.82% (32.92–81.56)  
7–13 
9/11 18.18% (2.28–51.78) 
Elecsys Anti-SARS-CoV-2 S 2/11 81.82% (48.22–97.72)  
≥14 49/76 35.53% (24.88–47.34)  
0/76 100.00% (95.26–100.00) 
GZ, gray zone. 
a For antibody assays with a gray zone, two calculations were performed. In the first calculation, all gray zone results were excluded from the analysis (GZ excl.) and 
in the second calculation these results were interpreted as reactive (GZ+). 
E. Riester et al.                                                                                                                                                                                                                                  
Journal of Virological Methods 297 (2021) 114271
7
timing of these responses (Kohmer et al., 2020; Wang et al., 2020; Van 
Elslande et al., 2020; Johnson et al., 2020; Burbelo et al., 2020). How-
ever, differences between N- and S- antigen-based assays should be 
taken into consideration when interpreting results. 
A major strength of this study is the large cohort of presumed 
negative samples collected before the COVID-19 pandemic from multi-
ple sites that were used to determine the specificity of the assay, as well 
as the multiple method comparison analyses performed and the various 
population cohorts used, with samples from pediatrics and from preg-
nant women. Further studies should be performed to determine the 
sensitivity of the Elecsys Anti-SARS-CoV-2 S immunoassay on a larger 
sample group. 
The Elecsys Anti-SARS-CoV-2 S assay could be used to support studies 
requiring quantification of antibody responses and vaccine efficacy 
studies and may be particularly useful due to the majority of vaccines 
being based on the S protein. Previous studies have utilized the Elecsys 
Anti-SARS-CoV-2 S immunoassay to determine the immune response to 
vaccination in various populations (Salvagno et al., 2021; Kennedy et al., 
2021; Herishanu et al., 2021; Cavalcanti et al., 2021; Callegaro et al., 
2021; Seyahi et al., 2021), as well as to quantify antibody levels 
(Rubio-Acero et al., 2021; Resman Rus et al., 2021), although further 
evaluation is necessary to assess the performance of the Elecsys 
Anti-SARS-CoV-2 S immunoassay for these specific purposes as assessing 
vaccine efficacy is currently outside of the intended use of the assay. 
5. Conclusion 
This study demonstrated the performance of the Elecsys Anti-SARS- 
CoV-2 S immunoassay, with a very high specificity of 99.95% (7876/ 
7880) and sensitivity of 97.92% (235/240) in samples ≥14 days post- 
PCR confirmation, which was comparable to other commercially avail-
able immunoassays. Therefore, these data support the use of the Elecsys 
Anti-SARS-CoV-2 S immunoassay for reliable identification of past 
exposure to SARS-CoV-2 in various populations, and highlight the po-
tential for the use of this assay in determining immune status during 
vaccine efficacy studies. 
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